The molecular docking studies further provided insights into the compounds’ interactions with critical cancer-related targets, including estrogen receptor alpha (ESR1), human topoisomerase II alpha (TOP2A), and cyclin-dependent kinase 5 (CDK5), suggesting that these compounds may be valuable in cancer therapy. The gene discussed is ESR1; the disease is cancer.